Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) announced its earnings results on Friday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Appili Therapeutics Stock Performance
Shares of OTCMKTS:APLIF opened at $0.01 on Friday. The company has a market capitalization of $1.20 million, a PE ratio of -0.23 and a beta of -0.04. The business’s fifty day simple moving average is $0.01 and its 200-day simple moving average is $0.01. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03.
About Appili Therapeutics
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Featured Stories
- Five stocks we like better than Appili Therapeutics
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
